Indoco Remedies Ltd’s Goa manufacturing facility has cleared a key regulatory inspection by the UK Medicines and Healthcare Products Regulatory Agency (UKMHRA), with no critical or major observations reported.

 

The UKMHRA conducted a current Good Manufacturing Practices (cGMP) inspection of the company’s solid dosages manufacturing facility, Plant I, in Goa from September 7 to September 9, 2026.

 

The successful inspection provides a significant regulatory boost to the facility, which supplies products to several regulated international markets, including the UK, Europe, South Africa, New Zealand, Australia and Canada.

 

Commenting on the development, Aditi Panandikar, Managing Director - Indoco Remedies Ltd. said, "This plant has been consistently catering to the regulated markets of UK, Europe, South Africa, New Zealand, Australia and Canada for several years and is expected to contribute to approx. 30% of total international business. 

 

"The successful completion of the UKMHRA cGMP inspection with no critical or major observations is a strong validation of our robust quality systems. This further testifies our unwavering commitment to Good Manufacturing Practices and world class quality standards. The accolade not only reinforces the trust our global partners place in us, but strengthens our ability to serve patients worldwide."